The title compound, C(5)H(6)N(3)O(2) (+)·ClO(4) (-), is comprised of discrete perchlorate anions and 2-amino-3-nitro-pyridinium cations. The anion has a typical tetra-hedral geometry while the cation presents a nearly planar [maximum deviation = 0.007 (8) Å] pyridinium ring. Undulating [C(5)H(6)N(3)O(2) (+)](n) chains extending along the c-axis direction are linked via N-H⋯O hydrogen bonds. The cations are further connected to the anions by N-H⋯O hydrogen bonds and weak C-H⋯O inter-actions, leading to the formation of a three-dimensional network.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2979774PMC
http://dx.doi.org/10.1107/S1600536810000425DOI Listing

Publication Analysis

Top Keywords

n-h⋯o hydrogen
8
hydrogen bonds
8
2-amino-3-nitro-pyridinium perchlorate
4
perchlorate title
4
title compound
4
compound c5h6n3o2
4
c5h6n3o2 +·clo4
4
+·clo4 comprised
4
comprised discrete
4
discrete perchlorate
4

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

AIMST University, Bedong, Kedah, Malaysia.

Background: Senile dementia (SD) is a deteriorative organic brain disorder and it comprises Alzheimer's disease (AD) as a major variant. SD is shown impairment of mental capacities whereas AD is degeneration of neurons. According to World Health Organization (WHO) report; more than 55 million peoples have dementia and it is raising 10 million new cases every year.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India.

Background: The present study recapitulates the potency of the novel synthesized piperazine-benzoquinone derivative as a lead molecule selectively targeting AChE along with the antioxidative potential for the management of cognitive decline in Alzheimer's disease.

Method: Novel piperazine-benzoquinone derivative was synthesized implementing appropriate synthetic procedures and was characterized by various spectral and elemental techniques. The purity of this synthetic analogue was ascertained by TLC, melting point determination and elemental analyses.

View Article and Find Full Text PDF

Background: Neurological disorders are at epidemic levels in the world today. Various proteins are being targeted for the development of novel molecular therapeutics; however, no small-molecule inhibitors have been discovered. Recent studies suggest that there are few molecules in clinical trials for various secretase (α, β, and γ), caspase, and calpain inhibitors.

View Article and Find Full Text PDF

Green separation of protein (e.g., bovine serum albumin (BSA)) by low-melting mixture solvents (LoMMSs) depends on the underlying mechanism between BSA and LoMMSs.

View Article and Find Full Text PDF

A series of chiral hybrid diphosphorus ligands incorporating a conformationally flexible tropos diphenylmethane-based phosphoramidite unit have been developed and evaluated in the Rh-catalyzed asymmetric hydrogenation of 2-(1-arylvinyl)anilides and α-enamides, leading to up to >99% yield and 99% enantiomeric excess. Preliminary results from comparative studies showcased the extraordinary catalytic performance of these chiral tropos phosphine-phosphoramidite ligands, with a competency essentially superior to those of well-established ligands with a regular rigid backbone.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!